Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perspective TherapeuticsFRA:AAJ0 -9.08%33 EBIT per Share is €-1.21 as of Mar. 2026. GuruFocus rates FRA:AAJ0 with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 685 Medical Devices & Instruments companies, Perspective Therapeutics ranks worse than 95.04% on this metric.
Perspective Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.22.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.21.
During the past 3 years, the average EBIT per Share Growth Rate was -46.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -15.70% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 2.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Perspective Therapeutics's EBIT per Share or its related term are showing as below:
FRA:AAJ0'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -423.1 Med: 19.1 Max: 80.6
Current: -46.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Perspective Therapeutics was 80.60% per year. The lowest was -423.10% per year. And the median was 19.10% per year.
FRA:AAJ0's 3-Year EBIT Growth Rate is ranked worse than 95.04% of 685
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs FRA:AAJ0: -46.30
Perspective Therapeutics (FRA:AAJ0) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Perspective Therapeutics EBIT per Share Related Terms
Perspective Therapeutics EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perspective Therapeutics (FRA:AAJ0) has a EBIT per Share of €-1.21 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Perspective Therapeutics and its competitors. According to the industry distribution chart, Perspective Therapeutics ranks #651 out of 685 companies in the Medical Devices & Instruments industry, placing it in the top 95%.
Is Perspective Therapeutics' EBIT per Share too high?
Perspective Therapeutics' current EBIT per Share is €-1.21. Based on the distribution chart, Perspective Therapeutics ranks #651 out of 685 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Perspective Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' EBIT per Share compare to ELMD and MASS?
According to the Medical Devices & Instruments industry distribution chart, Perspective Therapeutics ranks #651 out of 685 companies for EBIT per Share. This places Perspective Therapeutics in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Perspective Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perspective Therapeutics's current EBIT per Share is €-1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (FRA:AAJ0) has a current EBIT per Share of €-1.21. The current EBIT per Share is €-1.21. Perspective Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Perspective Therapeutics (FRA:AAJ0), the current EBIT per Share is €-1.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
33GF Score
Get the complete analysis for FRA:AAJ0
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AAJ0 has been successfully added to your 
